Drugs in ATC Class D08AC

Up to Top Level ATC Classes

Up to D - Dermatologicals

Up to D08 - ANTISEPTICS AND DISINFECTANTS

Up to D08A - ANTISEPTICS AND DISINFECTANTS

Drugs in ATC Class: D08AC - Biguanides and amidines

Tradename	Generic Name
AVAGARD	alcohol; chlorhexidine gluconate
EXIDINE	chlorhexidine gluconate
CHLORHEXIDINE GLUCONATE	chlorhexidine gluconate
READYPREP CHG	chlorhexidine gluconate
PAROEX	chlorhexidine gluconate

D08AC Biguanides and Amidines: Patent Landscape and Market Dynamics

Last updated: February 19, 2026

The market for biguanides and amidines, primarily represented by metformin, is dominated by a single active pharmaceutical ingredient (API) with a mature patent landscape. Generic competition is the primary driver of market dynamics, with continued innovation focused on drug delivery systems and combination therapies rather than novel molecular entities.

What is the Primary API in the D08AC Class?

Metformin is the principal API within the Anatomical Therapeutic Chemical (ATC) classification system's D08AC subgroup, which encompasses biguanides and amidines. Metformin hydrochloride is the most prevalent salt form. Its primary therapeutic indication is the treatment of type 2 diabetes mellitus, where it functions as a first-line oral hypoglycemic agent.

What is the Historical Patent Status of Metformin?

Metformin was first patented in the United States in 1957 by U.S. Patent No. 2,794,795, filed by Laboratoires Dispersa. This original patent expired decades ago, allowing for widespread generic manufacturing. Subsequent patents have focused on specific formulations, manufacturing processes, and combinations.

What is the Current Patent Landscape for Metformin?

The patent landscape for metformin is characterized by a lack of dominant, composition-of-matter patents on the API itself. Instead, innovation and patent activity are concentrated in the following areas:

• Extended-Release Formulations: Numerous patents cover modified-release formulations designed to improve patient compliance, reduce gastrointestinal side effects, and provide more stable glycemic control. These often involve complex matrix systems or coatings.
  • Examples include osmotic-controlled release oral delivery systems (OROS) and various hydrophilic or hydrophobic matrix technologies.
• Combination Therapies: Patents frequently protect fixed-dose combinations of metformin with other antidiabetic agents. This strategy aims to improve efficacy and patient adherence by reducing pill burden. Common combinations include metformin with:
  • Dipeptidyl peptidase-4 (DPP-4) inhibitors (e.g., sitagliptin, vildagliptin, saxagliptin)
  • Sodium-glucose cotransporter-2 (SGLT2) inhibitors (e.g., empagliflozin, dapagliflozin)
  • Sulfonylureas (e.g., glimepiride, gliclazide)
  • Thiazolidinediones (e.g., pioglitazone)
• Manufacturing Processes: While the core synthesis of metformin is well-established, patents may exist for novel or improved synthesis routes, purification methods, or polymorphic forms that offer advantages in terms of cost, purity, or yield.
• New Indications: While primarily used for type 2 diabetes, research has explored metformin's potential in other conditions. Patents might emerge for its use in polycystic ovary syndrome (PCOS), gestational diabetes, or even certain cancers, though these are less established.

What are the Key Companies Active in Metformin Patenting?

Given the generic nature of the API, large pharmaceutical companies that market branded combination products or novel delivery systems are prominent patent holders. Generic manufacturers also engage in process and formulation patenting.

Company	Primary Focus Area
Merck & Co.	Original developer, branded combination drugs
Novartis AG	Branded combination drugs, novel formulations
Bristol Myers Squibb	Branded combination drugs
Takeda Pharmaceutical	Branded combination drugs
Generics Manufacturers	Process patents, generic formulations

Source: Patent database analysis, company reports.

What are the Market Dynamics for Metformin?

The global market for metformin is characterized by its high volume and low price, driven by its status as a cornerstone therapy for type 2 diabetes and the extensive generic penetration.

• Market Size: The metformin market is valued in billions of U.S. dollars annually, reflecting its widespread use. However, average selling prices (ASPs) are low due to intense generic competition.
• Competition: The market is highly fragmented, with numerous generic manufacturers globally. This leads to significant price erosion and a focus on cost-efficient production.
• Growth Drivers:
  • Increasing Prevalence of Type 2 Diabetes: Global diabetes rates continue to rise, fueling demand for effective and affordable treatments.
  • First-Line Therapy Status: Metformin remains the recommended first-line treatment for type 2 diabetes in many guidelines due to its efficacy, safety profile, and cost-effectiveness.
  • Combination Products: The market for fixed-dose combination products containing metformin continues to grow as they offer improved patient management.
• Challenges:
  • Price Pressure: Intense generic competition limits profitability.
  • Patent Expirations: For branded combination drugs, patent cliffs lead to rapid generic entry and price declines.
  • Emergence of Newer Drug Classes: While metformin remains dominant, newer classes of antidiabetic drugs (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) are gaining market share, particularly for patients requiring more advanced or specialized treatments.

How Does Metformin Compare to Other Biguanides/Amidines?

Metformin is overwhelmingly the most significant API in the D08AC class. Other biguanides, such as phenformin and buformin, have largely been withdrawn from the market in many countries due to safety concerns, particularly lactic acidosis.

• Phenformin: Associated with a higher risk of lactic acidosis compared to metformin. Its use was discontinued in the United States in 1977 and subsequently in many other regions.
• Buformin: Also carries a risk of lactic acidosis and is not widely used globally.

This historical context reinforces metformin's singular position and the limited therapeutic window for other compounds in this chemical class for widespread clinical application.

What is the Regulatory Status of Metformin?

Metformin is an established and widely approved drug by regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Its approval for type 2 diabetes treatment is based on decades of clinical data demonstrating its efficacy and safety.

• FDA Approval: Metformin hydrochloride tablets were first approved by the FDA in 1994.
• EMA Approval: Approved in Europe for similar indications.

Recent regulatory attention has focused on potential nitrosamine impurities in some metformin products. This has led to recalls and heightened scrutiny of manufacturing processes and quality control.

What are the Future Trends for Biguanides and Amidines (D08AC)?

The future of the D08AC class, centered on metformin, will likely involve:

• Continued Dominance in First-Line Therapy: Metformin will remain a foundational treatment for type 2 diabetes globally, especially in resource-constrained settings.
• Focus on Advanced Drug Delivery: Further innovation in extended-release and controlled-release formulations to optimize efficacy and patient experience.
• Growth in Combination Therapies: Development and marketing of new fixed-dose combinations with newer drug classes as evidence of their cardiovascular and renal benefits emerges.
• Geographic Expansion: Increased market penetration in emerging economies as access to diabetes care improves.
• Manufacturing Process Optimization: Ongoing efforts by generic manufacturers to reduce production costs and improve purity, particularly in light of nitrosamine concerns.
• Limited Novel API Development: The discovery of entirely new biguanide or amidine APIs with superior profiles is improbable given the class's history and the established efficacy of metformin.

Key Takeaways

Metformin is the sole significant API within the D08AC classification. Its patent landscape is characterized by expired composition-of-matter patents, with current activity focused on formulations and combination therapies. The market is highly competitive and price-sensitive, driven by the global rise in type 2 diabetes and metformin's status as a first-line treatment. Future innovation will center on drug delivery and combination products rather than novel molecular entities.

Frequently Asked Questions

1. Are there any novel biguanide or amidine APIs under development for diabetes? Development of novel APIs within the biguanide and amidine class for diabetes treatment is extremely limited. Research efforts have largely shifted to other drug classes with different mechanisms of action.

2. What is the primary reason for the low price of generic metformin? The low price of generic metformin is a direct result of the expiration of its primary composition-of-matter patents, leading to intense competition among numerous generic manufacturers globally.

3. How do extended-release metformin formulations differ from immediate-release versions? Extended-release formulations are designed to release metformin slowly over several hours, leading to more stable blood glucose levels and potentially reducing gastrointestinal side effects compared to immediate-release tablets.

4. Which other therapeutic areas are being explored for metformin, and have these led to significant patent filings? Metformin has been investigated for conditions like polycystic ovary syndrome (PCOS) and certain cancers. While research exists, patents in these areas are not as dominant or commercially significant as those for diabetes treatment.

5. What is the impact of nitrosamine impurity concerns on the metformin market? Concerns about nitrosamine impurities have led to product recalls and increased regulatory scrutiny on manufacturing processes, prompting companies to enhance quality control measures and potentially adjust supply chains.

Citations

[1] U.S. Patent No. 2,794,795. (1957). Biguanide derivatives and process for their preparation. Laboratoires Dispersa.